EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey

Mustafa Murat Mıdık iD, Gökhan Şahin iD, Bekir Mert Durukan, Fatih Kuş iD, Kübra Haşimoğlu Gürün, Sinan Ünal, Cem Mirili iD, Canan Karan, Engin Hendem iD, Teoman Şakalar, Miray Aydoğan iD, Bahadır Köylü iD und 19 weitere

Journal of Clinical Medicine · 01.08.2026 · 15 (15) · 5997

DOI: 10.3390/jcm15155997 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 01.08.2026. Verfasst von Mustafa Murat Mıdık und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ege University Medical Faculty, 35100 Izmir, Turkey. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. Although the STRIDE regimen (durvalumab plus tremelimumab) has demonstrated an overall survival benefit in clinical trials, real-world evidence remains limited, particularly in Turkish clinical practice. This study aimed to evaluate the effectiveness and safety of first-line STRIDE therapy in patients with unresectable HCC treated in routine clinical practice.

Methods

We conducted a retrospective multicenter study including patients with unresectable HCC who received first-line durvalumab plus tremelimumab through the Turkish national Early Access Program across 18 oncology centers. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and exploratory Cox regression analyses were performed to evaluate baseline prognostic factors.

Results

Thirty-two patients were included. The median PFS was 7.25 months (95% CI, 3.68–22.29), and the median OS was 11.43 months (95% CI, 4.50–not reached). The underlying liver disease etiology was non-viral in 53.1% of patients, hepatitis B virus in 40.6%, and hepatitis C virus in 6.3%. Grade ≥ 3 treatment-related adverse events occurred in fewer than 10% of patients.

Conclusions

In this multicenter real-world cohort, first-line durvalumab plus tremelimumab appeared to be a feasible treatment option and was generally well tolerated in patients with unresectable HCC. However, given the retrospective design, small sample size, and absence of a control group, these findings should be interpreted cautiously and require confirmation in larger prospective comparative studies.

Schlagwörter

Stichwörter der Autor:innen

durvalumabhepatocellular carcinomaimmunotherapyreal worldsafetytremelimumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Ege University Medical Faculty, 35100 Izmir, Turkey.
  • Department of Medical Oncology, Hacettepe University, 06800 Ankara, Turkey.
  • Department of Medical Oncology, Ankara Sanatorium Hospital, 06290 Ankara, Turkey.
  • Department of Medical Oncology, Ondokuz Mayıs University, 55270 Samsun, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Atatürk Training and Research Hospital, Izmir Katip Çelebi University, 35620 Izmir, Turkey.
  • Department of Medical Oncology, Adana Middle East Hospital, 01140 Adana, Turkey.

ORCID-Profile: Mustafa Murat Mıdık, Gökhan Şahin, Fatih Kuş, Cem Mirili, Engin Hendem, Miray Aydoğan, Bahadır Köylü, Nadiye Sever, Oğuzhan Yıldız, Murat Alan, Nedim Turan, Mehmet Ali Şendur

Zitieren

APA

Mıdık, M. M., Şahin, G., Durukan, B. M., Kuş, F., Haşimoğlu Gürün, K., Ünal, S., Mirili, C., Karan, C., Hendem, E., Şakalar, T., Aydoğan, M., Köylü, B., Sever, N., Kaya, B. E., Kuş, T., Şencan, C., Erdoğan, A. P., Yaşar, H. A., Karakaş, H., …, & Yalçın, Ş. (2026). First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey. Journal of Clinical Medicine, 15(15), 5997. https://doi.org/10.3390/jcm15155997

Vancouver

Mıdık MM, Şahin G, Durukan BM, Kuş F, Haşimoğlu Gürün K, Ünal S, et al. First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey. Journal of Clinical Medicine. 2026;15(15):5997. doi:10.3390/jcm15155997

BibTeX
@article{Mdk2026,
  author = {Mıdık, Mustafa Murat and Şahin, Gökhan and Durukan, Bekir Mert and Kuş, Fatih and Haşimoğlu Gürün, Kübra and Ünal, Sinan and Mirili, Cem and Karan, Canan and Hendem, Engin and Şakalar, Teoman and Aydoğan, Miray and Köylü, Bahadır and Sever, Nadiye and Kaya, Bahattin Engin and Kuş, Tülay and Şencan, Canberk and Erdoğan, Atike Pınar and Yaşar, Hatime Arzu and Karakaş, Hilal and Yıldız, Oğuzhan and Yılmaz, Bahiddin and Alan, Murat and Çetin, Bülent and Turan, Nedim and Eryılmaz, Melek Karakurt and Artaç, Mehmet and Ünek, İlkay Tuğba and Selçukbiricik, Fatih and Şendur, Mehmet Ali and Yıldırım, Hasan Çağrı and Yalçın, Şuayib},
  title = {First-Line Durvalumab–Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {15},
  pages = {5997},
  doi = {10.3390/jcm15155997}
}
Kostenlos starten →